CA2897335A1 - A method for treating tumor by using recombinant interferon with changed spatial configuration - Google Patents

A method for treating tumor by using recombinant interferon with changed spatial configuration Download PDF

Info

Publication number
CA2897335A1
CA2897335A1 CA2897335A CA2897335A CA2897335A1 CA 2897335 A1 CA2897335 A1 CA 2897335A1 CA 2897335 A CA2897335 A CA 2897335A CA 2897335 A CA2897335 A CA 2897335A CA 2897335 A1 CA2897335 A1 CA 2897335A1
Authority
CA
Canada
Prior art keywords
administration
days
cancer
months
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2897335A
Other languages
English (en)
French (fr)
Inventor
Guangwen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Superlab Far East Ltd
Original Assignee
Superlab Far East Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Superlab Far East Ltd filed Critical Superlab Far East Ltd
Publication of CA2897335A1 publication Critical patent/CA2897335A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
CA2897335A 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration Abandoned CA2897335A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749570P 2013-01-07 2013-01-07
US61/749,570 2013-01-07
US201361779711P 2013-03-13 2013-03-13
US61/779,711 2013-03-13
PCT/CN2014/000019 WO2014106459A2 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration

Publications (1)

Publication Number Publication Date
CA2897335A1 true CA2897335A1 (en) 2014-07-10

Family

ID=51062515

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2897335A Abandoned CA2897335A1 (en) 2013-01-07 2014-01-07 A method for treating tumor by using recombinant interferon with changed spatial configuration
CA2897312A Active CA2897312C (en) 2013-01-07 2014-01-07 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2897312A Active CA2897312C (en) 2013-01-07 2014-01-07 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon

Country Status (10)

Country Link
US (6) US20160022778A1 (enExample)
EP (3) EP2941266B1 (enExample)
JP (5) JP2016508987A (enExample)
KR (4) KR20210069127A (enExample)
CN (2) CN104902917A (enExample)
AU (2) AU2014204386B2 (enExample)
CA (2) CA2897335A1 (enExample)
HK (2) HK1216394A1 (enExample)
TW (3) TWI718086B (enExample)
WO (2) WO2014106459A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
CN107847564B (zh) * 2015-05-12 2021-11-09 远东超级实验室有限公司 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CN108721603B (zh) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 干扰素α-1a在制备用于治疗癌症的药物中的用途
KR101880015B1 (ko) * 2017-12-08 2018-07-19 아주대학교산학협력단 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물
WO2020112991A1 (en) * 2018-11-27 2020-06-04 The Children's Hospital Of Philadelphia Compositions and methods for treating cancer
US20220251605A1 (en) * 2019-06-14 2022-08-11 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
CN111658779A (zh) * 2020-06-22 2020-09-15 四川大学华西医院 治疗新型冠状病毒肺炎的联合用药物
WO2022156735A1 (zh) * 2021-01-21 2022-07-28 厦门特宝生物工程股份有限公司 一种基于干扰素的癌症治疗方法和药物组合
US11759434B2 (en) * 2022-02-03 2023-09-19 Sytheon Limited Methods and compositions for treating melanoma and non-melanoma skin cancers
CN114533706B (zh) * 2022-02-15 2022-10-14 深圳市利云德生物技术有限公司 一种用于防治呼吸道疾病的雾化吸入制剂及其应用
WO2024076973A1 (en) * 2022-10-04 2024-04-11 Brown University Compositions and methods of delivering large proteins
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2005169A (en) * 1932-08-27 1935-06-18 Rowe Andrew Reed Casting metal ingots
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
PL172758B1 (pl) 1992-10-19 1997-11-28 Dura Pharma Inc Inhalator do proszków suchych PL PL PL PL PL PL PL
AU5883694A (en) 1993-01-19 1994-08-15 Glaxo Group Limited Device
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
EP0861321B1 (en) 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US6065472A (en) 1996-01-03 2000-05-23 Glaxo Wellcome Inc. Multidose powder inhalation device
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
JP3983985B2 (ja) * 2000-03-22 2007-09-26 株式会社東芝 ＭｘＡタンパク質の多型遺伝子およびその使用
IL155741A0 (en) 2000-11-03 2003-12-23 Pbl Biomedical Lab Interferons, uses and compositions related thereto
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
US8158145B2 (en) 2002-02-19 2012-04-17 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption type plaster
WO2004091571A2 (en) 2003-04-08 2004-10-28 New Jersey Institute Of Technology (Njit) Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
MY141751A (en) * 2003-08-28 2010-06-30 Sichuan Biotechnology Res Ct Recombinant super-compound interferon
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
ES2473622T3 (es) * 2003-08-28 2014-07-07 Superlab Far East Limited Usos de interferones con estructura espacial alterada
WO2005021777A2 (en) 2003-08-28 2005-03-10 Huiyangtech (Usa), Inc. Uses of spatial configuration to modulate protein function
CN1910195A (zh) * 2003-08-28 2007-02-07 辉阳科技美国公司 通过空间构象调节蛋白质功能
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
US20080102114A1 (en) * 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
CN1740197B (zh) 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
EP1868636A4 (en) * 2005-03-09 2012-03-28 Guangwen Wei USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2006133088A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
US8071125B2 (en) 2005-12-09 2011-12-06 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Transdermal patch containing isosorbide dinitrate and bisoprolol
EP2056883B1 (en) 2006-08-04 2021-09-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
EP2413901A4 (en) * 2009-03-30 2015-05-06 Cerulean Pharma Inc POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
EP2239580B1 (en) 2009-04-09 2013-03-27 Lga Biotecnologie Srl Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
CA2812644A1 (en) 2010-09-27 2012-04-05 Zestagen, S.A. Compositions and methods for treating neoplasia
US9107887B2 (en) * 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
US20130184437A9 (en) 2011-06-08 2013-07-18 Guangwen Wei Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
US20130273527A1 (en) * 2012-04-13 2013-10-17 Superlab Far East Limited Method for inducing cell senescence by recombinant interferon with altered spatial configuration
AU2013293049A1 (en) * 2012-07-20 2015-02-26 La Trobe University Method of diagnosis and treatment
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
KR102230547B1 (ko) 2013-11-13 2021-03-22 수퍼랩 파 이스트 리미티드 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도

Also Published As

Publication number Publication date
TW201427682A (zh) 2014-07-16
US20180326012A1 (en) 2018-11-15
EP2941264B1 (en) 2021-03-10
AU2014204368A1 (en) 2015-08-20
TWI726291B (zh) 2021-05-01
HK1216394A1 (zh) 2016-11-11
EP2941266A2 (en) 2015-11-11
US10874716B2 (en) 2020-12-29
KR20150139824A (ko) 2015-12-14
US20220339255A1 (en) 2022-10-27
EP2941264A4 (en) 2016-08-31
US20210260164A1 (en) 2021-08-26
WO2014106492A2 (en) 2014-07-10
EP3895725A3 (en) 2021-12-01
WO2014106459A8 (en) 2015-08-06
KR20150103284A (ko) 2015-09-09
EP2941266A4 (en) 2016-09-07
WO2014106459A2 (en) 2014-07-10
US20180344811A1 (en) 2018-12-06
AU2014204368B2 (en) 2018-08-23
AU2014204386A1 (en) 2015-08-27
CA2897312C (en) 2022-11-01
TWI718086B (zh) 2021-02-11
EP3895725A2 (en) 2021-10-20
US20150352188A1 (en) 2015-12-10
US20160022778A1 (en) 2016-01-28
KR20210077005A (ko) 2021-06-24
TW201940189A (zh) 2019-10-16
CN104902917A (zh) 2015-09-09
HK1217897A1 (en) 2017-01-27
HK1217178A1 (en) 2016-12-30
HK1214528A1 (zh) 2016-07-29
CN104994866A (zh) 2015-10-21
WO2014106492A3 (en) 2014-08-28
JP2020023547A (ja) 2020-02-13
CA2897312A1 (en) 2014-07-10
JP2020105223A (ja) 2020-07-09
US12109250B2 (en) 2024-10-08
JP2016508987A (ja) 2016-03-24
KR20210069127A (ko) 2021-06-10
JP2022031331A (ja) 2022-02-18
TW201427681A (zh) 2014-07-16
WO2014106459A3 (en) 2014-09-04
JP2016506413A (ja) 2016-03-03
EP2941264A2 (en) 2015-11-11
EP2941266B1 (en) 2022-05-25
AU2014204386B2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
US20220339255A1 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
Hermsen et al. Response to radiation therapy in adrenocortical carcinoma
HK1217178B (en) Recombinant interferon with changed spatial configuration for use in the treatment of malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion
Greten Treatment of liver cancer
Leon-Ferre et al. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature
US20250195917A1 (en) Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (start-fit) for hepatocellular carcinoma
Byeon et al. Developed operation method for patient-drived orthotopic xenograft model of hepatocellular carcinoma
WO2022166794A1 (zh) 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
Huang et al. The effect of fluorouracil controlled release formulation in the treatment of 32 cases with advanced colorectal cancer by local implant

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190104

EEER Examination request

Effective date: 20190104

EEER Examination request

Effective date: 20190104

EEER Examination request

Effective date: 20190104

FZDE Discontinued

Effective date: 20240227